Long time MannKind supporter Joshua Rodriguez says goodbye
Oct 7, 2016 15:21:18 GMT -5
sla55 and compound26 like this
Post by rajreddy on Oct 7, 2016 15:21:18 GMT -5
Joshua is a blogger with investment knowledge. But, he never mentioned whether he is a long or short on any of his stocks and he covers a huge number of companies with limited analysis. As an example, he was super bullish on SUNE all the way to bankruptcy; even claiming that each share is $14 dollars worth incase SUNE wants to sell the company and there is no chance of filing for bankruptcy. He kept saying the same until a few days before SUNE filed for bankruptcy. Having said that, Joshua still wants Afrezza to be successfull as he personally know how great the product is; he mentioned once that one of his family members used this product and that person felt like he/she got freedom by using Afrezza...! I agree such things happens with any investor.
On the other hand, Nate Pile kept his money where his mouth is and he never ruled out bankruptcy scenario. For the last few months, Nate suggested that invest only that money you are willing to lose on this particular stock; atleast he provided detailed analysis. He is a investor with great returns. I suggest you to look into his public news letters and I saw that only MNKD is struggling; there are few other stocks that lost some value but thats ok.
Looking at various Mannkind 2.0 developments in the last few months and not having a great turn around in sales of the great product (black box label application in the next few weeks, Afrezza pediatric work with JDRF, other formulations in Phase1 trails), I believe Matt and his team are working on a buyout plan and I am sure that there are a couple of Big Pharma companies looking at this; especially those loosing their insulin market. After looking at various articles on JDRF walk and Afrezza talks, I am pretty sure that Afrezza will enter into "Pediatric" Phase 2 in the next few months and if approved by FDA by the end of 2017 as a pediatric medication, then thats a game changer. Also, EPI-Haler is in development; Matt mentioned this in early 2016 but no one showed interest in it until Mylan's recent problems.
Personally, I wish Mannkind survive until Peditatric Afrezza trails are finished through some capital investments and that will sky rocket the sales.
On the other hand, Nate Pile kept his money where his mouth is and he never ruled out bankruptcy scenario. For the last few months, Nate suggested that invest only that money you are willing to lose on this particular stock; atleast he provided detailed analysis. He is a investor with great returns. I suggest you to look into his public news letters and I saw that only MNKD is struggling; there are few other stocks that lost some value but thats ok.
Looking at various Mannkind 2.0 developments in the last few months and not having a great turn around in sales of the great product (black box label application in the next few weeks, Afrezza pediatric work with JDRF, other formulations in Phase1 trails), I believe Matt and his team are working on a buyout plan and I am sure that there are a couple of Big Pharma companies looking at this; especially those loosing their insulin market. After looking at various articles on JDRF walk and Afrezza talks, I am pretty sure that Afrezza will enter into "Pediatric" Phase 2 in the next few months and if approved by FDA by the end of 2017 as a pediatric medication, then thats a game changer. Also, EPI-Haler is in development; Matt mentioned this in early 2016 but no one showed interest in it until Mylan's recent problems.
Personally, I wish Mannkind survive until Peditatric Afrezza trails are finished through some capital investments and that will sky rocket the sales.
